SCHEMBL1390819

SCHEMBL1390819

CCOc1nc(NCc2ccco2)nc(Nc2cccc(-c3nc4ccccc4s3)c2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.57
▸ KMT2A Q03164 5/20 0.57
▸ MAPK1 P28482 3/20 0.57
▸ NPSR1 Q6W5P4 3/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ HTT P42858 1/20 0.50
▸ KCNH3 Q9ULD8 2/20 0.49
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ AURKB Q96GD4 2/20 0.47
▸ EGFR P00533 2/20 0.47
▸ IGF1R P08069 2/20 0.47
▸ SRC P12931 2/20 0.47
▸ KDR P35968 2/20 0.47
▸ AURKA O14965 1/20 0.47
▸ INSR P06213 1/20 0.47
▸ FLT4 P35916 1/20 0.47
▸ SOS1 Q07889 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1391228 0.85 MAPT (0.58) MAPTKMT2AMAPK1NPSR1ALDH1A1
SCHEMBL1391051 0.82 MAPT (0.56) MAPTKMT2AMAPK1NPSR1ALDH1A1
Hydrochloric Acid SCHEMBL1390771 0.81 MAPT (0.55) MAPTKMT2AMAPK1NPSR1ALDH1A1
SCHEMBL10243636 0.81 MAPT (0.79) MAPTKMT2AMAPK1NPSR1ALDH1A1
SCHEMBL1391195 0.80 MAPT (0.69) MAPTKMT2AMAPK1NPSR1ALDH1A1
SCHEMBL1392162 0.80 MAPT (0.63) MAPTKMT2AMAPK1NPSR1ALDH1A1
SCHEMBL1390767 0.80 MAPT (0.63) MAPTKMT2AMAPK1NPSR1ALDH1A1
SCHEMBL1391604 0.79 MAPT (0.67) MAPTKMT2AMAPK1NPSR1ALDH1A1
SCHEMBL1391723 0.79 MAPT (0.67) MAPTKMT2AMAPK1NPSR1ALDH1A1
SCHEMBL10282725 0.79 MAPT (0.59) MAPTKMT2AMAPK1NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
EP-2231624-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF Progenics Pharmaceuticals, Inc. (US) 2010-09-29 — — EP disclosed
WO-2009091388-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF PROGENICS PHARMACEUTICALS, INC. (US) 2009-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof HAVCR2, ZC3HAV1, MAVS MAPT 3654/4885KMT2A 4066/4885MAPK1 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback